Safely Guiding the Immune System to Fight Disease
Eradivir develops antibody-recruiting molecules that selectively target diseased cells and activate a precise immune response to eliminate them.
Our Vision
Our goal is to focus the power of the immune system to treat disease. Our small molecule based Bispecific Antigenic immuno-Therapy (BAiT) technology tethers a patient’s immune cells specifically to a diseased cell facilitating its rapid and selective destruction. With a toolkit of these antibody recruiting small molecules, we will develop pharmaceuticals to treat and cure multiple diseases, from viral infections to cancer.
Rethinking Influenza
Our lead molecule, EV25, has been shown to be more effective than the current standard of care against all strains of influenza. EV25 functions by binding to infected cells and recruiting anti-hapten antibodies, enabling the body's innate immune system to rapidly clear the disease.
Learn more about EV25Eradivir has assembled a team of seasoned industry leaders, world class scientists and expert advisors.
